PIK3CA and cervical cancer: Considering the significant role of aberrant activation of the PI3K/AKT signaling pathway, the inhibitory effects of PI3K α-selective inhibitor BYL719 were evaluated in HPV-ind (C-33A) and HPV-asso cervical cancer cell lines (SiHa and MS751).